Is GenSight Biologics S.A. (GSGTF) a Buy, Sell, or Hold?
OTC : GSGTF
GenSight Biologics S.A. — News
$0.09 USD
$0 (0.0%)
- Volume
- 756
- Average Volume
- 6
- Market Capitalization
- $14.67M
- P/E Ratio
- -1.02
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.48
- Year Low
- $0.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.39
| Source | Headline |
|---|---|
|
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2026, and provided business updates. Cash Position as of June 30, 2026 GenSight Biologics' cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared t. businesswire.com - 2026-07-08 13:11:00 |
|
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders' vote at the Combined Shareholders' Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved. businesswire.com - 2026-05-20 12:00:00 |
|
GenSight Biologics to Hold its Combined General Meeting on May 19, 2026
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that its Combined General Meeting will be held tomorrow, Tuesday, May 19, 2026, at 2:00 p.m. CEST and will be broadcast live via the following link: GENSIGHT BIOLOGICS - Assembl. businesswire.com - 2026-05-18 12:30:00 |
|
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company's gene therapy investigational product for the treatment of ND4-LHO. businesswire.com - 2026-05-11 12:30:00 |
|
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 19, 2026, at 2:00 pm CEST at the Company's headquarters at 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast. businesswire.com - 2026-04-28 14:35:00 |
